Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

1 September 2024 (08:33 - 08:51)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Pablo Garcia-Pavia

Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda (Spain)

4 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Doctor C. Ho (Boston, US)

Presentation thumbnail

Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

Doctor C. Coats (Glasgow, GB)

Abstract Slides Video

Presentation thumbnail

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

Mr B. Van Driel (Amsterdam, NL)

Abstract Slides Video

Presentation thumbnail

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

Doctor A. Masri (Portland, US)

Abstract Slides Video

Access the full session

Session thumbnail

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

The Event

Event poster

ESC Congress 2024

1 September 2024 08:33 CET

You may be interested in

Congress Presentation

Long-term effects of mavacamten treatment in obstructive hypertrophic cardiomyopathy (HCM): updated cumulative analysis of the EXPLORER cohort of MAVA-long-term extension (LTE) study up to 120 weeks

Congress Presentation

Changes in standard of care (SOC) medication during long-term mavacamten treatment for obstructive hypertrophic cardiomyopathy (HCM): results from the EXPLORER cohort of MAVA-Long-Term Extension (LTE)

Congress Presentation

Patient case 2

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources